Xeris Biopharma Holdings, Inc. (XERS) stock
Close on Nov 13, 2026Market cap $3.04BP/E –Yield –
Xeris Biopharma Holdings, Inc. grew revenue 38.4% to $368.26M over the twelve months to Sep 30, 2026. Operating income rose 377.3% to $46.78M, moving the operating margin from 3.7% to 12.7%. At the latest close the market valued the company at $3.04B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.04B
- P/E ratio
- –
- Price to sales
- 8.25
- Price to book
- 62.26
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $368.26M
- Net income
- -$6.50M
- EPS, diluted
- -$0.06
- Book value per share
- $0.26
- Diluted shares
- 190M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $16.65
- Open
- $16.59
- Day's range
- $16.31 – $16.76
- Volume
- 3,399,068
- Average volume (20 days)
- 3,465,684
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- Beta (5 years)
- 1.15
- 52-week range
- $5.25 – $16.88
- RSI (14 days)
- 85.4
- Volatility (1 year)
- 57.1%
- Relative volume
- 1.39×
- WACC
- 10.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | XERS | S&P 500 | Difference | XERS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +63.3% | -3.0% | +66.4 pts | ||
| 3 months | +100.0% | -2.8% | +102.8 pts | ||
| Year to date | +112.2% | +11.5% | +100.7 pts | ||
| 1 year | +129.5% | +13.5% | +116.0 pts | ||
| 3 years | +928.4% | +77.7% | +850.7 pts | +117.5% | +21.1% |
| 5 years | +678.5% | +72.6% | +605.9 pts | +50.7% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Xeris Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Xeris Biopharma
Pharmaceutical Preparations
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with chronic endocrine and neurological conditions. Its commercial portfolio includes Recorlev, a cortisol synthesis inhibitor prescribed for adults with endogenous Cushing’s syndrome who cannot undergo or have not been cured by surgery; Gvoke, a ready-to-use liquid glucagon administered for severe hypoglycemia in pediatric and adult diabetes patients; and Keveyis, a treatment for primary periodic paralysis. The company also advances development pipeline candidates such as XP-8121 for hypothyroidism and collaborates with external pharmaceutical partners using its proprietary formulation platforms.
Company profile, executives and historyXeris Biopharma stock: common questions
What is Xeris Biopharma's stock price?
XERS closed at $16.66 on Nov 13, 2026, up 0.06% on the day. Over the past 52 weeks it traded between $5.25 and $16.88.
What is Xeris Biopharma's market cap?
Xeris Biopharma was worth $3.04B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is XERS's P/E ratio?
Xeris Biopharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.06), so it has no meaningful P/E ratio.
How much revenue does Xeris Biopharma make?
Xeris Biopharma reported revenue of $368.26M for the twelve months to Sep 30, 2026, up 38.4% from a year earlier.
Does Xeris Biopharma pay a dividend?
No. Xeris Biopharma has not paid a cash dividend over the last twelve months.
When does Xeris Biopharma report earnings next?
Xeris Biopharma is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has XERS stock performed over the past year?
Including dividends, XERS returned +129.5% over the past year, against +13.5% for the S&P 500.
How many XERS shares are sold short?
9M shares were sold short at the latest FINRA report, 5.20% of the float, or 4.3 days of average trading volume.
Who are Xeris Biopharma's competitors?
Companies most similar to Xeris Biopharma by business, industry and size include CORT, ARDX, ETON, HRMY, PHAR.
See a number that looks wrong?